BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sakaizawa K, Ashida A, Uchiyama A, Ito T, Fujisawa Y, Ogata D, Matsushita S, Fujii K, Fukushima S, Shibayama Y, Hatta N, Takenouchi T, Uehara J, Okuyama R, Yamazaki N, Uhara H. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. Journal of Dermatological Science 2015;80:33-7. [DOI: 10.1016/j.jdermsci.2015.07.012] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Furue M, Kadono T. Melanoma therapy: Check the checkpoints. J Dermatol 2016;43:121-4. [PMID: 26813076 DOI: 10.1111/1346-8138.13257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
2 Salgado MTSF, Fernandes E Silva E, Matsumoto AM, Mattozo FH, Amarante MCA, Kalil SJ, Votto APS. C-phycocyanin decreases proliferation and migration of melanoma cells: In silico and in vitro evidences. Bioorg Chem 2022;122:105757. [PMID: 35339928 DOI: 10.1016/j.bioorg.2022.105757] [Reference Citation Analysis]
3 Anderson-Vildósola J, Hernández-Martín Á. Addressing Frequently Asked Questions and Dispelling Myths About Melanocytic Nevi in Children. Dermatol Clin 2022;40:51-9. [PMID: 34799035 DOI: 10.1016/j.det.2021.09.005] [Reference Citation Analysis]
4 Matsui Y, Sasaki J, Takatsuka S, Takenouchi T. Trends in the prognosis of metastatic melanoma in the era of targeted therapy and immunotherapy: A single‐institution survey in Japan. J Dermatol 2021;48:75-9. [DOI: 10.1111/1346-8138.15642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kiniwa Y, Okuyama R. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma. Jpn J Clin Oncol 2021;51:315-20. [PMID: 33338202 DOI: 10.1093/jjco/hyaa222] [Reference Citation Analysis]
6 Namikawa K, Yamazaki N. Targeted Therapy and Immunotherapy for Melanoma in Japan. Curr Treat Options Oncol 2019;20:7. [PMID: 30675668 DOI: 10.1007/s11864-019-0607-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
7 Hu S, Chen Y, Zhao B, Yang N, Chen S, Shen J, Bao G, Wu X. KIT is involved in melanocyte proliferation, apoptosis and melanogenesis in the Rex Rabbit. PeerJ 2020;8:e9402. [PMID: 32596061 DOI: 10.7717/peerj.9402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Fujimura T, Fujisawa Y, Kambayashi Y, Aiba S. Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. Cancers (Basel) 2019;11:E1342. [PMID: 31514399 DOI: 10.3390/cancers11091342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
9 Gong HZ, Zheng HY, Li J. The clinical significance of KIT mutations in melanoma: a meta-analysis. Melanoma Res 2018;28:259-70. [PMID: 29746316 DOI: 10.1097/CMR.0000000000000454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
10 Kaji T, Yamasaki O, Takata M, Otsuka M, Hamada T, Morizane S, Asagoe K, Yanai H, Hirai Y, Umemura H, Iwatsuki K. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity. Journal of Dermatological Science 2017;85:51-7. [DOI: 10.1016/j.jdermsci.2016.10.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
11 Ruksha TG, Sergeeva EY, Fefelova YA, Khorzhevsky VA. [The significance of C-KIT gene mutations in the diagnosis and prognosis of malignant tumors]. Arkh Patol 2021;83:61-8. [PMID: 34278763 DOI: 10.17116/patol20218304161] [Reference Citation Analysis]
12 Yamamoto Y, Matsusaka K, Fukuyo M, Rahmutulla B, Matsue H, Kaneda A. Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis. Cancer Med 2020;9:7194-204. [PMID: 32406600 DOI: 10.1002/cam4.3127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med 2021;10:2293-9. [PMID: 33686688 DOI: 10.1002/cam4.3781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Nakamura Y, Namikawa K, Yoshino K, Yoshikawa S, Uchi H, Goto K, Nakamura Y, Fukushima S, Kiniwa Y, Takenouchi T, Uhara H, Kawai T, Hatta N, Funakoshi T, Teramoto Y, Otsuka A, Doi H, Ogata D, Matsushita S, Isei T, Hayashi T, Shibayama Y, Yamazaki N. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol 2020;31:1198-206. [PMID: 32522691 DOI: 10.1016/j.annonc.2020.05.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
15 Yokomichi H, Inozume T, Wada M, Asai J, Igaki H, Namikawa K, Hayashi A, Fukushima S, Fujimura T, Koga H, Nakamura Y, Mochizuki M, Yamagata Z. Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)V600E Status in Metastatic against Primary Lesion of Melanoma: A Meta-analysis. JMA J 2020;3:274-9. [PMID: 33150263 DOI: 10.31662/jmaj.2020-0016] [Reference Citation Analysis]
16 Hennessey RC, Holderbaum AM, Bonilla A, Delaney C, Gillahan JE, Tober KL, Oberyszyn TM, Zippin JH, Burd CE. Ultraviolet radiation accelerates NRas-mutant melanomagenesis: A cooperative effect blocked by sunscreen. Pigment Cell Melanoma Res 2017;30:477-87. [PMID: 28544727 DOI: 10.1111/pcmr.12601] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
17 Kiyohara T, Nagano N, Miyamoto M, Shijimaya T, Nakamaru S, Makimura K, Tanimura H. BRAF ‐mutated, acral verrucous melanoma successfully treated by dabrafenib plus trametinib combination therapy. Clin Exp Dermatol 2019;44:945-6. [DOI: 10.1111/ced.13976] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ito T, Kaku-Ito Y, Murata M, Ichiki T, Kuma Y, Tanaka Y, Ide T, Ohno F, Wada-Ohno M, Yamada Y, Oda Y, Furue M. Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis. Int J Mol Sci 2019;20:E6191. [PMID: 31817947 DOI: 10.3390/ijms20246191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
19 Fujimura T, Hidaka T, Kambayashi Y, Aiba S. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. Expert Opin Investig Drugs 2019;28:143-8. [PMID: 30556435 DOI: 10.1080/13543784.2019.1558442] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
20 Nakamura Y, Asai J, Igaki H, Inozume T, Namikawa K, Hayashi A, Fukushima S, Fujimura T, Ito T, Imafuku K, Tanaka R, Teramoto Y, Minagawa A, Miyagawa T, Miyashita A, Wada M, Koga H, Sugaya M. Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019. J Dermatol 2020;47:89-103. [DOI: 10.1111/1346-8138.15151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
21 Hayakawa K, Wakimoto H, Mae K, Irisawa R, Harada K. Efficacy and safety of full-dose dabrafenib and trametinib combination therapy in a patient on hemodialysis with metastatic melanoma. Int J Dermatol 2021;60:516-7. [PMID: 33165909 DOI: 10.1111/ijd.15298] [Reference Citation Analysis]
22 Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murao N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med 2019;8:2146-56. [PMID: 30932370 DOI: 10.1002/cam4.2110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
23 Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol 2020;61:139-48. [PMID: 31655118 DOI: 10.1016/j.semcancer.2019.09.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
24 Min K, Choe J, Kwon MJ, Lee HK, Kang HS, Nam ES, Cho SJ, Park H, Min SK, Seo J, Kim YJ, Kim NY, Kim HY. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis. Pathology - Research and Practice 2019;215:152671. [DOI: 10.1016/j.prp.2019.152671] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Fujisawa Y, Ito T, Kato H, Irie H, Kaji T, Maekawa T, Asai J, Yamamoto Y, Fujimura T, Nakai Y, Yasuda M, Matsuyama K, Muto I, Matsushita S, Uchi H, Nakamura Y, Uehara J, Yoshino K. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases. Eur J Cancer 2021;145:210-20. [PMID: 33503528 DOI: 10.1016/j.ejca.2020.12.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, Takatsuka S, Koga H, Wada N, Minami H, Hatsumichi M, Asada S, Namba Y, Yamazaki N. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. Eur J Cancer 2018;105:114-26. [PMID: 30447539 DOI: 10.1016/j.ejca.2018.09.025] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
27 Sheen Y, Tan K, Tse K, Liao Y, Lin M, Chen J, Liau J, Tseng Y, Lee C, Hong C, Liao J, Chang H, Chu C. Genetic alterations in primary melanoma in Taiwan. Br J Dermatol 2020;182:1205-13. [DOI: 10.1111/bjd.18425] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
28 Yamazaki N, Kiyohara Y, Uhara H, Uehara J, Fujisawa Y, Takenouchi T, Otsuka M, Uchi H, Ihn H, Hatsumichi M, Minami H. Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. Cancer Sci 2019;110:1995-2003. [PMID: 30959557 DOI: 10.1111/cas.14015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
29 Takahashi A, Namikawa K, Nakano E, Yamazaki N. Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma. J Dermatol 2020;47:257-64. [PMID: 31876308 DOI: 10.1111/1346-8138.15204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
30 Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, Takatsuka S, Koga H, Wada N, Minami H, Hatsumichi M, Namba Y, Yamazaki N. Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma. J Dermatol 2020;47:1257-66. [PMID: 32812243 DOI: 10.1111/1346-8138.15514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Uhara H. Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. Int J Clin Oncol 2019;24:1508-14. [PMID: 29470725 DOI: 10.1007/s10147-018-1246-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Nepote A, Avallone G, Ribero S, Cavallo F, Roccuzzo G, Mastorino L, Conforti C, Paruzzo L, Poletto S, Carnevale Schianca F, Quaglino P, Aglietta M. Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. JCM 2022;11:828. [DOI: 10.3390/jcm11030828] [Reference Citation Analysis]
33 Fujimura T, Kambayashi Y, Sato Y, Tanita K, Tono H, Lyu C, Takahashi T, Hashimoto A, Aiba S. Successful treatment of unresectable recurrent programmed death ligand 1 moderately-expressing malignant melanoma of the nasal cavity with pembrolizumab monotherapy. J Dermatol 2019;46:e260. [PMID: 30672615 DOI: 10.1111/1346-8138.14786] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Tsutsumida A, Fukushima S, Yokota K, Yoshikawa S, Yamasaki O, Tanemura A, Okuyama R, Uhara H, Muto Y, Miyashita A, Akiyama M, Kaji T, Koga H, Kato J, Katayama T, Itakura E, Yamazaki N, Kiyohara Y. Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma. J Dermatol 2019;46:947-55. [DOI: 10.1111/1346-8138.15073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
35 Nomura M, Oze I, Masuishi T, Yokota T, Satake H, Iwasawa S, Kato K, Andoh M. Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma. Int J Clin Oncol 2020;25:972-7. [PMID: 31938955 DOI: 10.1007/s10147-020-01618-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
36 Uhara H, Kiyohara Y, Tsuda A, Takata M, Yamazaki N. Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan. Clin Transl Oncol 2018;20:169-75. [PMID: 28674996 DOI: 10.1007/s12094-017-1706-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
37 Fayne RA, Macedo FI, Rodgers SE, Möller MG. Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. Oncol Rev 2019;13:433. [PMID: 31857858 DOI: 10.4081/oncol.2019.433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open 2021;6:100325. [PMID: 34839104 DOI: 10.1016/j.esmoop.2021.100325] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Ide T, Ito T, Wada-Ohno M, Furue M. Preoperative Screening CT and PET/CT Scanning for Acral Melanoma: Is it Necessary? J Clin Med 2021;10:811. [PMID: 33671347 DOI: 10.3390/jcm10040811] [Reference Citation Analysis]
40 Takahashi A, Namikawa K, Ogata D, Nakano E, Jinnai S, Nakama K, Tsutsui K, Muto Y, Mizuta H, Yamazaki N. Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. J Dermatol 2020;47:1267-75. [PMID: 32725685 DOI: 10.1111/1346-8138.15521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
41 Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. Front Immunol 2021;12:680407. [PMID: 34149718 DOI: 10.3389/fimmu.2021.680407] [Reference Citation Analysis]
42 Yamazaki N, Tsutsumida A, Takahashi A, Namikawa K, Yoshikawa S, Fujiwara Y, Kondo S, Mukaiyama A, Zhang F, Kiyohara Y. Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma. J Dermatol 2018;45:397-407. [PMID: 29399853 DOI: 10.1111/1346-8138.14210] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
43 Takai E, Omata W, Totoki Y, Nakamura H, Shiba S, Takahashi A, Namikawa K, Mori T, Yamazaki N, Shibata T, Yachida S. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. Cancer Sci 2021. [PMID: 34477284 DOI: 10.1111/cas.15088] [Reference Citation Analysis]
44 Rinonce HT, Sastri DJ, Trisnawati F, Kameswari B, Ferronika P, Irianiwati. The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia. Cancer Rep (Hoboken) 2021;:e1454. [PMID: 34110110 DOI: 10.1002/cnr2.1454] [Reference Citation Analysis]
45 Moon KR, Choi YD, Kim JM, Jin S, Shin M, Shim H, Lee J, Yun SJ. Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features. Journal of Investigative Dermatology 2018;138:933-45. [DOI: 10.1016/j.jid.2017.11.017] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
46 Fujiwara Y, Yamazaki N, Kiyohara Y, Yoshikawa S, Yamamoto N, Tsutsumida A, Nokihara H, Namikawa K, Mukaiyama A, Zhang F, Tamura T. Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study. Invest New Drugs 2018;36:259-68. [PMID: 28879519 DOI: 10.1007/s10637-017-0502-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
47 Nakamura K, Okuyama R. Immunotherapy for advanced melanoma: Current knowledge and future directions. Journal of Dermatological Science 2016;83:87-94. [DOI: 10.1016/j.jdermsci.2016.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
48 Wada M, Ito T, Tsuji G, Nakahara T, Hagihara A, Furue M, Uchi H. Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan. J Dermatol 2017;44:932-8. [PMID: 28342269 DOI: 10.1111/1346-8138.13834] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
49 Ito T, Kaku-Ito Y, Murata M, Furue K, Shen CH, Oda Y, Furue M. Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival. J Clin Med 2020;9:E690. [PMID: 32143442 DOI: 10.3390/jcm9030690] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
50 Gutiérrez-Castañeda LD, Nova JA, Tovar-Parra JD. Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review. Melanoma Res 2020;30:62-70. [PMID: 31274706 DOI: 10.1097/CMR.0000000000000628] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
51 Meng D, Carvajal RD. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. Am J Clin Dermatol 2019;20:315-23. [PMID: 30707374 DOI: 10.1007/s40257-018-0414-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
52 Chang JW, Guo J, Hung CY, Lu S, Shin SJ, Quek R, Ying A, Ho GF, Nguyen HS, Dhabhar B, Sriuranpong V, Tiambeng ML, Prayogo N, Yamazaki N. Sunrise in melanoma management: Time to focus on melanoma burden in Asia. Asia Pac J Clin Oncol 2017;13:423-7. [PMID: 28198155 DOI: 10.1111/ajco.12670] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
53 Hirai I, Tanese K, Fukuda K, Fusumae T, Nakamura Y, Sato Y, Amagai M, Funakoshi T. Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol. Medicine (Baltimore) 2021;100:e27832. [PMID: 34889232 DOI: 10.1097/MD.0000000000027832] [Reference Citation Analysis]